Direct Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Hypertrophic Cardiomyopathy: A Retrospective Cohort Study - PubMed
3 hours ago
- #Atrial Fibrillation
- #Anticoagulation
- #Hypertrophic Cardiomyopathy
- Study compares direct oral anticoagulants (DOACs) versus warfarin in patients with atrial fibrillation (AF) and hypertrophic cardiomyopathy (HCM).
- DOACs showed a lower incidence of ischemic stroke (3.5%) compared to warfarin (4.8%), with a hazard ratio (HR) of 0.74.
- All-cause mortality was similar between DOACs (16.8%) and warfarin (17.4%) groups.
- DOACs had lower all-cause hospitalization rates (64.5%) compared to warfarin (68.7%).
- No significant differences were found in rates of acute myocardial infarction, gastrointestinal bleeding, hematuria, or intracranial hemorrhage between the two groups.
- The study supports the use of DOACs over warfarin in patients with AF and HCM due to better outcomes in stroke prevention and hospitalization rates.